drugset / Trial / NCT01460199

Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease

NCT01460199

Phase 1 Completed 33 enrolled Concert Pharmaceuticals
RandomizedParallel-groupTriple-blindTreatment

Summary

This study is being conducted to evaluate the safety and tolerability of treatment with CTP-499 in non-dialysis patients associated with moderate chronic kidney disease.

Timeline

Start
2011-08
Primary completion
2011-12
Completion
2011-12

Drugs

EvaluationDrugModalityDoseRoute
Subject CTP-499 Small molecule 600 mg